nach oben

Drugs

Erschienen in:

01.10.2005 | Adis Drug Profile

Palifermin

In Myelotoxic Therapy-Induced Oral Mucositis

verfasst von: M. Asif A. Siddiqui, Keri Wellington

Erschienen in: Drugs | Ausgabe 15/2005

Einloggen, um Zugang zu erhalten

Abstract

▴ Palifermin, a recombinant human keratinocyte growth factor (KGF), mimics the actions of endogenous KGF and has shown efficacy in the management of myelotoxic therapy-induced oral mucositis in cancer patients.

▴ In a randomised, double-blind trial in patients with haemtaological malignancies receiving conditioning radiochemotherapy before undergoing autologous stem cell transplant, intravenous palifermin 60 μg/kg/day (two 3-day cycles, administered before myelotoxic therapy and after transplant) significantly reduced the median duration (primary endpoint) [3 vs 9 days] and incidence (63% vs 98%) of WHO grade 3 or 4 oral mucositis, compared with placebo.

▴ Patient-reported outcomes also showed significant improvement with palifermin treatment, which was associated with significant reductions in healthcare resource utilisation, compared with placebo.

▴ The drug was generally well tolerated, with skin/ oral toxicities, pain/arthralgias and dysaesthesia being the most common palifermin-related adverse reactions.

The use of trade names is for product identification purposes only and does not imply endorsement.

Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100 (9 Suppl.): 1995–2025PubMedCrossRef

Elting LS, Cooksley C, Chambers M. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003; 98(7): 1531–9PubMedCrossRef

Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19(8): 2201–5PubMed

Bellm LA, Epstein JB, Rose-Ped A, et al. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000; 8(1): 33–9PubMed

Ruescher TJ, Sodeifi A, Scrivani SJ, et al. The impact of mucositis on α-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998; 82(11): 2275–81PubMedCrossRef

Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100 (9 Suppl.): 2026–46PubMedCrossRef

auf dem Keller U, Krampert M, Kümin A, et al. Keratinocyte growth factor: effects on keratinocytes and mechanisms of action. Eur J Cell Biol 2004; 83(11–12): 607–12

Amgen Inc. Product information (US): Kepivance™ (palifermin 6.25mg) lyophilized powder for IV injection [online]. Available from URL: http://www.kepivance.com [Accessed 2005 Aug 16]

Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351(25): 2590–8PubMedCrossRef

10.

Meropol NJ, Somer RA, Gutheil J, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003 Apr 15; 21(8): 1452–8PubMedCrossRef

11.

Clarke SJ, Abdi E, Davis ID, et al. Recombinant human keratinocyte growth factor (rHuKGF) prevents chemotherapy-induced mucositis in patients with advanced colorectal cancer: a randomized phase II trial [abstract no. 1529]. Proc Am Soc Clin Oncol 2001; 20 (Pt 1): 383a

12.

Dörr W, Spekl K, Farrell CL. Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int J Radiat Oncol Biol Phys 2002; 54(1): 245–51PubMedCrossRef

13.

Dörr W, Bässler S, Reichel S, et al. Reduction of radiochemotherapy-induced early oral mucositis by recombinant human keratinocyte growth factor (palifermin): experimental studies in mice. Int J Radiat Oncol Biol Phys 2005; 62(3): 881–7PubMedCrossRef

14.

Zia-Amirhosseini P, Salfi M, Leese P, et al. Pharmacokinetics and pharmacodynamics of palifermin (a r-huKGF molecule) in healthy volunteers after intravenous administration of single escalating doses up to 250 mcg/kg [abstract no. 5036]. Blood 2004; 104 (11 Pt 2): 341–2

15.

Ning S, Shui C, Khan WB, et al. Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. Int J Radiat Oncol Biol Phys 1998; 40(1): 177–87PubMedCrossRef

16.

Serdar CM, Heard R, Prathikanti R, et al. Safety, pharmacokinetics and biologic activity of rHuKGF in normal volunteers: results of a placebo-controlled randomized double-blind phase 1 study [abstract no. 761]. Blood 1997; 90 (Suppl. 1. Pt 1): 172

17.

Durrant S, Pico JL, Schmitz N, et al. A phase I study of recombinant human keratinocyte growth factor (rHuKGF) in lymphoma patients receiving high-dose chemotherapy (HDC) with autologous peripheral blood progenitor cell transplantation (AUTOPBPCT) [abstract no. 3130]. Blood 1999; 94 (10 Suppl. 1 Pt 1): 708

18.

Spielberger RT, Stiff P, Emmanouilides C, et al. Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning: results of a phase 2 trial [abstract no. 25]. Proc Am Soc Clin Oncol 2001; 20 (Pt 1): 7a

19.

Emmanouilides C, Spielberger R, Stiff P, et al. Palifermin treatment of mucositis in transplant patients reduces health resource use: phase 3 results [abstract no. 883]. Blood 2003; 102 (11 Pt 1): 251–2

20.

Elting LS, Shih YCT, Stiff PJ, et al. Palifermin reduces estimated downstream costs of autologous stem cell transplant (SCT): analysis of phase 3 trial results [abstract no. 2191]. Blood 2004; 104 (11 Pt 1): 602

Titel: Palifermin
In Myelotoxic Therapy-Induced Oral Mucositis
verfasst von: M. Asif A. Siddiqui
Keri Wellington
Publikationsdatum: 01.10.2005
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 15/2005
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200565150-00008

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 15/2005

Lansoprazole in the Treatment of Gastro-oesophageal Reflux Disease in Children and Adolescents

Palifermin in Myelotoxic Therapy-Induced Oral Mucositis

Palifermin in Myelotoxic Therapy-Induced Oral Mucositis

Infliximab

Pharmacological Treatment of Ankylosing Spondylitis

Palifermin in Myelotoxic Therapy-Induced Oral Mucositis